Welcome to our dedicated page for Viemed Healthcare news (Ticker: VMD), a resource for investors and traders seeking the latest updates and insights on Viemed Healthcare stock.
Viemed Healthcare Inc. (NASDAQ: VMD) delivers innovative respiratory care solutions through its home-based medical equipment and therapy services. This dedicated news hub provides investors and healthcare professionals with essential updates on corporate developments, clinical advancements, and regulatory milestones.
Access timely updates on earnings reports, product launches, and strategic partnerships that shape VMD's leadership in respiratory disease management. Our curated collection features official press releases alongside verified third-party analysis, ensuring comprehensive coverage of the company's home therapy innovations and equipment rental operations.
Key focus areas include updates on non-invasive ventilation technologies, sleep apnea treatment advancements, and partnerships with healthcare systems. Track developments in Medicare reimbursement policies affecting home care services and monitor VMD's expansion in neuromuscular disease management markets.
Bookmark this page for streamlined access to Viemed Healthcare's latest financial disclosures, regulatory filings, and clinical outcome reports. Stay informed about critical updates through our organized presentation of enterprise-wide developments in respiratory care innovation.
Viemed Healthcare reported strong Q3 2024 financial results with net revenues increasing 17.4% to $58.0 million, setting a company record. Net income rose 33% to $3.9 million ($0.10 per diluted share), while Adjusted EBITDA grew 15.5% to $14.0 million. The company expanded its ventilator patient count by 11.0% to 11,374 and increased sleep therapy patients by 11.0% to 19,478. With a strong cash balance of $11.3 million and $55.3 million available in credit facilities, Viemed projects Q4 2024 revenues between $59.7-60.9 million, exceeding previous guidance.
Viemed Healthcare, a national leader in respiratory care and technology-enabled home medical equipment services, has announced its upcoming third quarter 2024 earnings conference call. The call is scheduled for Thursday, November 7, 2024, at 12:00 p.m. EST.
Interested parties can participate in the call by dialing 877-407-6176 (US Toll-Free) or +1 201-689-8451 (International). A live audio webcast will also be available. Following the live call, a replay will be accessible in the Investor Relations section of Viemed's website at www.viemed.com.
Viemed Healthcare (NASDAQ:VMD) reported record second quarter 2024 financial results, with net revenues reaching $55.0 million, a 27% increase year-over-year and 9% sequential growth. The company achieved a net income of $1.5 million and Adjusted EBITDA of $12.8 million, up 31% from Q2 2023. Viemed's ventilator patient count grew to 10,905, a 4.4% sequential increase. The company maintains a strong financial position with $8.8 million in cash and $13.5 million in working capital. For Q3 2024, Viemed expects net revenues between $56.5 million and $57.7 million. CEO Casey Hoyt emphasized the company's strategy validation and leading position in complex respiratory care services.
Viemed Healthcare, a national leader in respiratory care and technology-enabled home medical equipment services, has announced its upcoming Quarterly Conference Call. The call is scheduled for Thursday, August 8, 2024, at 11:00 a.m. ET.
Interested parties can participate by dialing 888-437-3179 (US Toll-Free) or +1 862-298-0702 (International). Financial professionals are invited to pre-register by emailing investorinfo@viemed.com by 12:00 p.m. ET on Wednesday, August 7, 2024, to ask questions during the call.
A live audio webcast will be available, and following the call, a replay can be accessed in the Investor Relations section of Viemed's website.
Viemed Healthcare, Inc. announced its first quarter 2024 financial results, reporting net revenues of $50.6 million, a 28% increase from the same quarter last year. The company achieved a net income of $1.6 million and adjusted EBITDA of $10.1 million. Viemed also has a strong cash balance of $7.3 million, no net debt, and approximately $53 million available under credit facilities. The recent strategic partnership with East Alabama Health is expected to generate net revenues of $53.8-$54.8 million in the second quarter of 2024. CEO Casey Hoyt expressed optimism about the company's performance, highlighting investments in personnel, operational enhancements, and acquisition strategies.
FAQ
What is the current stock price of Viemed Healthcare (VMD)?
What is the market cap of Viemed Healthcare (VMD)?
